Acetanilides Adrenergic beta-3 Receptor Agonists Aged Humans Lower Urinary Tract Symptoms Male Prostatic Hyperplasia/complications/*drug therapy Randomized Controlled Trials as Topic Thiazoles Treatment Outcome Urinary Bladder Overactive/complications/*drug therapy Urological Agents Lower urinary tract symptoms Mirabegron Overactive Prostatic hyperplasia Urinary bladder

Mirabegron benign prostatic hyperplasia systematic review meta-analysis

Anticoagulants Humans Male Platelet Aggregation Inhibitors Postoperative Hemorrhage/chemically induced Prostatic Hyperplasia *Transurethral Resection of Prostate

5-alpha Reductase Inhibitors/*administration & dosage Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Drug Therapy Combination Dutasteride/*administration & dosage Erectile Dysfunction/chemically induced/diagnosis Humans Male Prostatic Hyperplasia/diagnosis/*drug therapy/epidemiology Randomized Controlled Trials as Topic/methods Tamsulosin/*administration & dosage Treatment Outcome Benign prostatic hyperplasia Dutasteride Meta-analysis Randomized controlled trials Tamsulosin published studies thus no ethical approval and patient consent are required. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Embolization Therapeutic Humans Male Prostate/*blood supply/pathology Prostatic Hyperplasia/diagnosis/*therapy Transurethral Resection of Prostate Treatment Outcome Benign prostatic hyperplasia Meta-analysis Prostatic artery embolization Transurethral resection of the prostate PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Humans Lower Urinary Tract Symptoms Male Phosphodiesterase 5 Inhibitors/administration & dosage/adverse effects Placebos Prostatic Hyperplasia/complications/*etiology Quality of Life Regression Analysis Severity of Illness Index Lower urinary tract symptoms Meta-analysis Phosphodiesterase 5 inhibitor Placebo Prostatic hyperplasia

Bladder-sparing strategy Clinical complete response Localized muscle-invasive bladder cancer Neoadjuvant Systemic treatment

Humans *Urinary Bladder Neoplasms *Carcinoma Transitional Cell/surgery/pathology Ureteroscopy/adverse effects/methods *Ureteral Neoplasms/surgery/pathology *Kidney Neoplasms/surgery/pathology Antegrade Endoscopic surgery Kidney-sparing surgery Retrograde Upper tract urothelial carcinoma

Diet Fruit Humans Male Prospective Studies Risk Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology *Vegetables

Female Gene Expression Profiling Gene Regulatory Networks Humans Male Muscles Neoplasm Invasiveness Prognosis *Urinary Bladder Neoplasms/genetics/metabolism rab GTP-Binding Proteins/genetics/metabolism Bladder cancer Gene expression Muscle-invasive bladder cancer Urothelial cancer

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

bladder cancer cohort cruciferous vegetables meta-analysis risk commercial or financial relationships that could be construed as a potential conflict of interest.

Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker

Bladder cancer complications cystectomy frailty mortality organisation regarding the material discussed in the manuscript.

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

Biomarkers Tumor/genetics Carcinoma/genetics Gene Expression/genetics Gene Expression Profiling/methods Gene Expression Regulation Neoplastic/genetics Humans Neoplasm Recurrence Local/genetics Odds Ratio Prognosis RNA Circular/*genetics Survival Analysis Transcriptome/genetics Urinary Bladder/pathology Urinary Bladder Neoplasms/*genetics/metabolism bladder cancer circular RNA meta-analysis

Case-Control Studies Humans *Polymorphism Single Nucleotide Promoter Regions Genetic Urinary Bladder Neoplasms/*genetics Vascular Endothelial Growth Factor A/*genetics Bladder cancer Meta-analysis Polymorphism Vascular endothelial growth factor competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

B7-H1 Antigen/*metabolism Biomarkers Tumor/metabolism Carcinoma Transitional Cell/metabolism/*mortality/pathology Cell Membrane/metabolism Gene Expression Regulation Neoplastic Humans Neoplasm Staging Prognosis Survival Analysis *Up-Regulation Urinary Bladder Neoplasms/metabolism/*mortality/pathology Biomarker Meta-analysis Pd-l1 Urothelial carcinoma

Cystectomy/*methods Humans Organ Sparing Treatments/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery Bladder preservation High-grade non-muscle-invasive bladder cancer Meta-analysis Radical cystectomy PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.